Remifentanil Hydrochloride
Injection
Current Active — Day 1416
Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.
FDA shortage record
- Substance
- Remifentanil Hydrochloride
- Manufacturers / suppliers
-
- Hikma Pharmaceuticals USA Inc.
- Hikma Pharmaceuticals USA, Inc.
- Dosage form
- Injection
- Presentation
- Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)
- Route(s)
- INTRAVENOUS
- Therapeutic category
- Analgesia/Addiction
- Package NDC
0143-9393-10- Initially posted
- 06/28/2022
- Days on shortage list
- 1416
- Current FDA status
- Current
- Shortage entries (current dataset)
- 2 records for Remifentanil Hydrochloride
Reason and context
Additional lots will be available. Product will be made available as it is released.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-631-2174.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
9d289052-1eb6-4ba2-a3ca-d2e542a052ae). - FDA UNII identifier:
5V444H5WIC. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.